The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations
Abstract
Objective: Phagocytes are extensively involved in the synovial inflammation associated with chronic arthritis. The aim of our study was to determine neutrophil activation in juvenile rheumatoid arthritis (JRA) by analyzing S100A12 (EN‐RAGE; calgranulin C), a proinflammatory protein secreted by human neutrophils. Methods: S100A12 serum concentrations were determined in 124 patients with chronic active polyarticular‐, oligoarticular‐, or systemic‐onset JRA. S100A12 was also analyzed in synovial fluid obtained from 22 patients. Changes in S100A12 levels in response to anti–tumor necrosis factor α (anti‐TNFα) therapy, intraarticular injections of corticosteroids, and methotrexate (MTX) treatment were analyzed. Forty‐five patients were followed up after successful antiinflammatory treatment, for a mean period of 2.8 years. Results: The mean serum level of S100A12 was 395 ng/ml in patients with active polyarticular JRA and 325 ng/ml in patients with active oligoarticular JRA (normal <120 ng/ml). The level of S100A12 was ∼10‐fold higher in synovial fluid than in serum, indicating release at sites of local inflammation. In patients with systemic‐onset JRA, the mean level of S100A12 was 3,700 ng/ml. Moreover, serum levels decreased in response to different antiinflammatory therapies (i.e., intraarticular injections of corticosteroids, MTX, or etanercept). S100A12 levels were elevated in 20 patients who experienced disease flares after the initial induction of remission, even weeks before the relapses became clinically apparent. Conclusion: S100A12 serum concentrations indicate neutrophil activation in JRA and correlate with disease activity. S100A12 may indicate synovial inflammation even when other signs of arthritis are absent. Its function as a proinflammatory factor secreted by activated neutrophils makes this protein a potential target for future therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of health status in children with juvenile rheumatoid arthritis
Singh, G., Athreya, B. H., Fries, J. F., & Goldsmith, D. P. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371209 · Cited by 838
Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17810 · Cited by 813
Rage and arthritis: The G82S polymorphism amplifies the inflammatory response
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., Lalla, E., Chitnis, S., Monteiro, J., Stickland, M. H., et al. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363861 · Cited by 383
Yeh, C.-H., Sturgis, L., Haidacher, J., Zhang, X.-N., Sherwood, S. J., Bjercke, R. J., Juhasz, O., Crow, M. T., Tilton, R. G., & Denner, L. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1495 · Cited by 326
Cited by
Ravelli, A., & Martini, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60363-8 · Cited by 1,993
Foell, D., Wittkowski, H., Vogl, T., & Roth, J. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306170 · Cited by 879
Self-citationMarenholz, I., Heizmann, C. W., & Fritz, G. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.096 · Cited by 848
Prakken, B., Albani, S., & Martini, A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60244-4 · Cited by 771
Juvenile Idiopathic Arthritis: Will Etanercept be an Improvement over Current Therapies?
De Benedetti, F., & Ravelli, A. (2000) · BioDrugs · doi:10.2165/00063030-200014020-00003 · Cited by 428
Metadata
- Authors
- Foell, D., Wittkowski, H., Hammerschmidt, I., Wulffraat, N., Schmeling, H., Frosch, M., Horneff, G., Kuis, W., Sorg, C., & Roth, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-04
- Volume
- 50
- Issue
- 4
- Pages
- 1286-1295
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1972409318
- Cited by
- 177
- References
- 4
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.